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Association of β-Amyloid Burden With Sleep Dysfunction
and Cognitive Impairment in Elderly Individuals
With Cognitive Disorders
Jason C. You, MD, PhD; Erica Jones, BS; Devon E. Cross, BS, BA; Abigail C. Lyon, PsyD; Hyunseung Kang, PhD; Andrew B. Newberg, MD; Carol F. Lippa, MD

Abstract
IMPORTANCE Evidence shows that sleep dysfunction and β-amyloid (Aβ) deposition work
synergistically to impair brain function in individuals with normal cognition, increasing the risk of
developing dementia later in life. However, whether Aβ continues to play an integral role in sleep
dysfunction after the onset of cognitive decline in individuals with dementia is unclear.

Key Points
Question Is β-amyloid deposition in the
brain associated with sleep dysfunction
and cognition in elderly individuals with
cognitive disorders?
Findings In this survey study of 52

OBJECTIVE To determine whether Aβ deposition in the brain is associated with subjective measures

participants aged 65 years and older,

of sleep quality and cognition in elderly individuals with cognitive disorders.

β-amyloid deposition in the precuneus
was associated with the number of

DESIGN, SETTING, AND PARTICIPANTS A nested survey study was conducted at the Cognitive

nocturnal awakenings, whereas

Disorders and Comprehensive Alzheimer Disease Center of Thomas Jefferson University Hospital in

β-amyloid deposition in the brainstem

Philadelphia, Pennsylvania. Participants included patients aged 65 years and older with cognitive

was associated with daytime sleepiness.

disorders verified by neuropsychological testing. Eligible participants were identified from a referral

Nocturnal awakenings, but not daytime

center–based sample of patients who underwent fluorine 18–labeled florbetaben positron emission

sleepiness, were associated with poor

tomography imaging at Thomas Jefferson University Hospital as part of the multicenter Imaging

cognition, and β-amyloid deposition was

Dementia-Evidence for Amyloid Scanning study. Data collection and analysis occurred between

indirectly associated with cognitive

November 2018 and March 2019.

impairment via nocturnal awakenings.
Meaning In elderly individuals with

MAIN OUTCOMES AND MEASURES Sleep quality was measured via responses to sleep
questionnaires, Aβ deposition was measured via fluorine 18–labeled florbetaben positron emission
tomography, and cognition was measured via Mini-Mental State Examination (MMSE) performance.

cognitive disorders, a mechanism that
involves disruption of nighttime sleep
may underlie the association between
β-amyloid deposition and cognitive

RESULTS Of the 67 eligible participants, 52 (77.6%) gave informed consent to participate in the

impairment.

study. Of the 52 enrolled participants (mean [SD] age, 76.6 [7.4] years), 27 (51.9%) were women.
Daytime sleepiness was associated with Aβ deposition in the brainstem (B = 0.0063; 95% CI, 0.001
to 0.012; P = .02), but not MMSE performance (B = −0.01; 95% CI, −0.39 to 0.37; P = .96). The
number of nocturnal awakenings was associated with Aβ deposition in the precuneus (B = 0.11; 95%
CI, 0.06 to 0.17; P < .001) and poor MMSE performance (B = −2.13; 95% CI, −3.13 to −1.13; P < .001).

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

Mediation analysis demonstrated an indirect association between Aβ deposition and poor MMSE
performance that relied on nocturnal awakenings as an intermediary (B = −3.99; 95% CI, −7.88 to
−0.83; P = .01).
CONCLUSIONS AND RELEVANCE Nighttime sleep disruption may mediate the association
between Aβ and cognitive impairment, suggesting that there is an underlying sleep-dependent
mechanism that links Aβ burden in the brain to cognitive decline. Further elucidation of this
mechanism may improve understanding of disease processes associated with Aβ accumulation.
JAMA Network Open. 2019;2(10):e1913383. doi:10.1001/jamanetworkopen.2019.13383

Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(10):e1913383. doi:10.1001/jamanetworkopen.2019.13383 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Thomas Jefferson University User on 11/14/2019

October 16, 2019

1/12

JAMA Network Open | Neurology

β-Amyloid Burden, Sleep Dysfunction, and Cognitive Impairment in Elderly Individuals

Introduction
Sleep dysfunction is associated with cognitive decline in the aging population.1,2 Increasing evidence
shows that sleep and circadian rhythm disturbances predispose the brain to accumulation of
β-amyloid (Aβ),1,3 a protein metabolite that impairs neuronal function and is linked to numerous
cognitive disorders, including Alzheimer disease (AD), dementia with Lewy bodies, Parkinson disease
dementia, cerebrovascular dementia, and frontotemporal dementia.4,5 Studies6-12 in humans have
shown that a variety of poor sleep indicators, including prolonged sleep latency, increased sleep
fragmentation, decreased total sleep time, and excessive daytime sleepiness, are associated with
increased Aβ deposition in the brain. Mechanistic studies have also demonstrated that sleep
disruption promotes Aβ accumulation by simultaneously upregulating Aβ synthesis13,14 and
interfering with Aβ clearance.14,15
Importantly, the relationship between sleep dysfunction and Aβ appears to be bidirectional
because elevated levels of Aβ in the brain also impair slow-wave sleep,16 thereby exacerbating sleep
problems.17,18 The synergistic relationship between Aβ abnormalities and sleep dysfunction has been
shown to interfere with memory consolidation and recall.9,16 Moreover, individuals with normal
cognition experiencing poor sleep quality have increased brain Aβ burden and are at higher risk of
developing dementia later in life.8,10,19,20
Notably, patients with cognitive disorders have profound disturbances in sleep architecture and
circadian rhythms.2,21 However, studies examining the association between Aβ and sleep have, thus
far, largely been performed in individuals with normal cognition, and whether Aβ continues to play an
important role in sleep dysfunction after the onset of cognitive decline is unclear. Therefore, this
study aims to examine the associations between Aβ abnormalities, subjective measures of sleep
quality, and cognitive function in elderly individuals with cognitive disorders.

Methods
Participants
All participants in this study were patients with cognitive disorders who received care at the
Cognitive Disorders and Comprehensive Alzheimer Disease Center at Thomas Jefferson University
Hospital, a major referral center in the Delaware Valley. The center is an outpatient clinic that serves
patients who are living independently, with family or caregivers, or in assisted living facilities.
Therefore, hospitalized patients or those living in nursing homes were not included in the study, even
though there were no specific exclusion criteria for these conditions. Inclusion criteria included age
65 years or older and a diagnosis of mild cognitive impairment (MCI) or dementia based on criteria
established by the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) and/or the
National Institutes of Aging and the Alzheimer Association. Patients with normal cognition or
subjective complaints unverified by cognitive testing were excluded from the study. Other major
exclusion criteria included cancer requiring active therapy, hip or pelvic fracture within the 12 months
before enrollment, and loss to follow-up. A sample of 80 patients who underwent Aβ positron
emission tomography (PET) imaging at Thomas Jefferson University Hospital as part of the
multicenter Imaging Dementia-Evidence for Amyloid Scanning Study (ClinicalTrials.gov identifier:
NCT02420756) were originally considered for this study. Of this sample, 67 patients were deemed
eligible for the study on the basis of the aforementioned criteria.
This study was approved by the institutional review board at Thomas Jefferson University
Hospital and was categorized as minimal risk. Verbal informed consent was obtained from
participants as they were contacted via phone for the study. The informed consent process included
education about protected health information, the purpose of the study, data to be gathered by the
investigators, risks of the study, steps taken to ensure participant privacy and confidentiality, and
information on how to withdraw consent. Participants were told that there was no monetary
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compensation for the study. This study follows the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline.22
Data collection and analysis occurred between November 2018 and March 2019. Data
pertaining to race/ethnicity were extracted from electronic health records and were based on the
participants’ own responses to previous health questionnaires. Race/ethnicity was subsequently
assessed as a potential confounding factor in the analyses.

Cognitive Assessment
Cognition was assessed via the participants’ most recent performance on the Mini-Mental State
Examination (MMSE). The MMSE is a 30-point questionnaire that is widely used to evaluate the
severity of cognitive impairment in individuals with cognitive disorders.23 The questionnaire tests
multiple cognitive domains, including orientation, attention and calculation, language, verbal
memory, and visuospatial planning. Score cutoffs for the MMSE are as follows: greater than or equal
to 24 for normal cognition, between 19 and 23 for MCI, between 10 and 18 for moderate cognitive
impairment, and less than or equal to 9 for severe cognitive impairment.24

Sleep Quality Assessment
Eligible participants and their family or caregivers were contacted via phone for sleep quality
assessment; 52 participants (77.6%) gave verbal informed consent to participate in the study.
Reasons for refusing consent included not wanting to share personal information over the phone (6
participants [40.0%]), inconvenient timing (3 participants [20.0%]), inaccessible after 3 or more
attempts (3 participants [20.0%]), no longer following up with a clinician at Thomas Jefferson
University Hospital (2 participants [13.3%]), and patient was deceased (1 participant [6.7%]). Sleep
quality was assessed via 2 sleep questionnaires that have previously been validated (eAppendix in
the Supplement).19,25 We made certain that participants with MMSE scores less than 24 had at least 1
family member or caregiver present during the questionnaire to corroborate their responses; those
with higher scores were also encouraged to respond jointly with family members to improve
response accuracy.

Brain Imaging and Regional Analysis
For Aβ PET imaging, participants were injected intravenously with fluorine 18–labeled florbetaben
tracer (Neuraceq; Piramel Imaging), and imaging was performed approximately 60 minutes later as
per a standard protocol using either PET–magnetic resonance imaging or PET–computed
tomography. Image processing was performed using MIMNeuro software (version 6.6, MIM
Software), and Aβ deposition in different brain regions was calculated via standardized uptake value
ratio. Regions of interest (ROIs) were based on susceptibility to Aβ deposition19,26 and included the
anterior and posterior cingulate gyrus, medial frontal lobe, medial and lateral temporal lobe,
precuneus, superior parietal lobe, thalamus, and brainstem.

Statistical Analysis
The deposition of Aβ across ROIs was analyzed via the Welch analysis of variance with the GamesHowell post hoc test, which helps to detect differences between samples with unequal variances.
Associations between Aβ deposition, different sleep measures, and MMSE performance were
analyzed via multiple linear regression. Data in regression analyses were modeled by least-squares
regression lines, with each line having a slope equivalent to the regression coefficient (B), also known
as regression weight. A Wald-type 95% CI for B was then calculated from the SE of the sampling
distribution of data points from the slope of the regression line. The strength of association between
variables of interest was determined by calculating the coefficient of determination (R2). Forward
stepwise regression was used to control for potentially confounding variables; this multivariate
regression method incorporates variables in stepwise fashion until the model fit is no longer
significantly improved via the F-test. Therefore, variables that make statistically significant
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contributions to the multivariate regression are distinguished from those that do not. The problem
of multiple comparisons was encountered when correlating data involving Aβ and was addressed via
2 methods: Bonferroni corrections for α levels and performing a limited number of planned
comparisons for specific ROIs based on hypotheses. It is important to mention that Aβ deposition
exhibits a high degree of collinearity across different cortical regions27; therefore, corrections for
multiple comparisons should be interpreted with caution because they can increase the risk of a type
II error.28 Comparative and regression analyses were performed using SPSS statistical software
version 25 (IBM). Unless otherwise stated, 2-sided hypothesis testing was conducted, with type I
error controlled at α = .05.
Mediation analysis was used to evaluate whether the association between Aβ deposition and
poor MMSE performance could be mediated by nocturnal awakenings. Mediation analysis is a
multivariate regression assay that uses a series of regressions to assess the strength of association
between 2 variables of interest (X and Y) under different conditions.29,30 These conditions are
defined by the presence or absence of a third variable (M) that is hypothesized to mediate the
association between X and Y. Regressions performed for mediation analysis can be represented
graphically by a pathway diagram that illustrates the relationship between X and Y with and without
considering M (ie, the indirect and direct pathways, respectively). By assessing the degree of
influence that M has on the association between X and Y, a regression coefficient for the mediation
effect of M can thus be calculated. In summary, mediation analysis assesses whether the association
between 2 variables is better explained by direct association (ie, does not require mediation) or
indirect association (ie, requires mediation by another variable). Matrix calculations and
bootstrapping for mediation analysis was performed via the PROCESS (version 3.3) macro for SPSS.29

Results
Overall, 52 participants (mean [SD] age, 76.6 [7.4] years) were included in the analyses (Table).
Among the 27 female participants (51.9%), the mean (SD) age was 77.8 (6.4) years (age range, 66-91
years). Among the 25 male participants (48.1%), the mean (SD) age was 75.4 (8.3) years (age range,
66-94 years). Among the female participants, 24 were white (88.9%), 2 were African American
(7.4%), and 1 was Hispanic (3.7%). Among the male participants, 22 were white (88.0%), 2 were
African American (8.0%), and 1 was Hispanic (4.0%). Using a standardized uptake value ratio
threshold of 1.2,31 elevated brain Aβ deposition was detected in 34 of the 52 participants (65.4%),
with levels of Aβ being highest in the precuneus, anterior cingulate gyrus, and brainstem relative to
other brain regions (eFigure in the Supplement). Of the participants with elevated brain Aβ
deposition, 16 (47.1%) were female and 18 (52.9%) were male. We found no significant difference in
tracer detection between participants who underwent PET–magnetic resonance imaging vs
PET–computed tomography (t5 = −0.22; P = .83).

Daytime Sleepiness, Aβ Deposition, and MMSE Performance
In this sample of individuals with cognitive disorders, we observed a significant positive association
between daytime sleepiness scores and Aβ deposition in the brainstem (B = 0.0063; 95% CI, 0.001
to 0.012; P = .02) (Figure 1A and D). However, daytime sleepiness was not associated with Aβ burden
in any other ROI, as demonstrated by the nonsignificant association between daytime sleepiness and
total brain Aβ deposition (B = 0.0023; 95% CI, −0.007 to 0.011; P = .62) (Figure 1B). Moreover, there
was no significant association between daytime sleepiness and MMSE performance (B = −0.01; 95%
CI, −0.39 to 0.37; P = .96) (Figure 1C).

Nocturnal Awakenings, Aβ Deposition, and MMSE Performance
The number of nocturnal awakenings reported by participants demonstrated a significant positive
association with total brain Aβ deposition (B = 0.041; 95% CI, 0.015 to 0.067; P = .003) (Figure 2A).
Subsequent regional analysis revealed that nocturnal awakenings had the strongest association with
JAMA Network Open. 2019;2(10):e1913383. doi:10.1001/jamanetworkopen.2019.13383 (Reprinted)
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Aβ deposition in the precuneus (B = 0.11; 95% CI, 0.06 to 0.17; P < .001) (Figure 2B) vs other brain
regions (eTable in the Supplement). Nocturnal awakenings also demonstrated a significant negative
association with MMSE performance (B = −2.13; 95% CI, −3.13 to −1.13; P < .001) (Figure 2C). Notably,
even after controlling for participant age, sex, race/ethnicity, total hours of nighttime sleep, sleep
apnea, sleep medication use, and dementia medication use, both the association between precuneus
Aβ deposition and nocturnal awakenings (B = 0.095; 95% CI, 0.023 to 0.17; P = .01) and the
association between nocturnal awakenings and poor MMSE performance (B = −1.64; 95% CI, −2.8 to
−0.48; P = .01) remained significant. We next assessed whether Aβ deposition had a direct
association with MMSE performance and found a significant but weak inverse association (B = −5.54;
95% CI, −10.24 to −0.85; P = .02) (Figure 2D). The inverse association between Aβ and MMSE
performance was no longer significant after controlling for participant age (B = −3.07; 95% CI, −7.6 to
1.46; P = .18).
Because Aβ is thought to primarily drive disease progression in AD, we also tested associations
between precuneus Aβ deposition, nocturnal awakenings, and MMSE performance in a subset of 34
participants with AD or amnestic MCI, a prodromal stage of AD.32 Similar to our overall findings,
nocturnal awakenings were positively associated with precuneus Aβ deposition (B = 0.097; 95% CI,
0.042 to 0.15; P = .001) and negatively associated with MMSE performance (B = −1.86; 95% CI,

Table. Participant Demographic and Clinical Characteristics
Chracteristica

Participants, No. (%)
(N = 52)

Demographic characteristics
Age, mean (SD), y

76.6 (7.4)

Female

27 (51.9)

Race/ethnicity
White

46 (88.5)

African American

4 (7.7)

Hispanic or Latino

2 (3.8)

Diagnosis
Alzheimer disease

21 (40.4)

Cerebrovascular dementia

4 (7.7)

Dementia with Lewy bodies

5 (9.6)

Parkinson disease dementia

1 (1.9)

Frontotemporal dementia

4 (7.7)

Amnestic mild cognitive impairment

7 (13.5)

Nonamnestic mild cognitive impairment

3 (5.8)

Mixed dementia

7 (13.5)

Alzheimer disease and cerebrovascular dementia

6 (11.5)

Hippocampal sclerosis and cerebrovascular dementia

1 (1.9)

Mini-Mental State Examination score, median (IQR)

24 (18.3-26.8)

Time elapsed since Mini-Mental State Examination, median (IQR), mo

13 (6-20)

β-Amyloid deposition, mean (SD), standardized uptake value ratio

1.2 (0.16)

Use of dementia medicationb

34 (65.4)

Abbreviation: IQR, interquartile range.
a

Data with normal distributions are reported using
mean (SD); data with nonnormal distributions are
reported using median (IQR).

b

Dementia medications include donepezil,
rivastigmine, and memantine.

c

The quality of the data was poor, with no response
from more than 10% of participants.

d

Sleep medications include benzodiazepines, Z-drugs,
mirtazapine, trazodone, quetiapine, tricylic
antidepressants, first-generation anticholinergics,
and melatonin.

e

Sleep quality and daytime sleepiness scores were
assessed via 2 sleep questionnaires that have
previously been validated (eAppendix in the
Supplement).19,25 Participants rated their sleep
quality on a scale of 0 (terrible) to 10 (excellent). A
daytime sleepiness score of 10 or greater indicates
excessive daytime sleepiness.

Sleep characteristics
Latency to sleep, median (IQR), minc

8.8 (5-18.1)

Total nighttime sleep, mean (SD), h

8.4 (2.3)

Nocturnal awakenings, median (IQR), No.

2 (1-2.5)

Difficulty returning to sleep ≥1 d/wkc

16 (34)

Snore

27 (51.9)

Sleep apnea

11 (21.1)

Use of sleep medicationd

13 (25)

Overall nighttime sleep quality score, median (IQR)e

8 (6-8)

Daytime sleepiness score, mean (SD)e

7.8 (5)
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−3.00 to −0.72; P = .002) in patients with AD or amnestic MCI. However, Aβ deposition and poor
MMSE performance were not significantly associated in this subgroup (B = −6.26; 95% CI, −13.19 to
0.62; P = .07).

Mediation Analysis of Aβ Deposition, Nocturnal Awakenings, and MMSE Performance
Given the much stronger association of Aβ deposition with nocturnal awakenings vs poor MMSE
performance, we hypothesized that Aβ did not have a direct association with poor cognition but
instead was associated with cognitive impairment indirectly via nocturnal awakenings as an
intermediary. This hypothesis is supported by previous studies9,16 showing that sleep modulates the
association between Aβ and cognition in individuals with normal cognition. To test whether a

Figure 1. Associations of Daytime Sleepiness Score (DSS) With β-Amyloid (Aβ) Deposition
and Mini-Mental State Examination (MMSE) Performance
A Brainstem Aβ deposition

D PET scans
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modulatory association of sleep with Aβ and cognition could also be present in individuals with
cognitive disorders, we used mediation analysis to assess whether nocturnal awakenings mediated
the association between Aβ and poor MMSE performance in our sample of participants. A full
description of mediation analysis is provided in the Statistical Analysis subsection of the
Methods section.
Figure 3 shows a graphical depiction of mediation analysis performed on data collected for
precuneus Aβ deposition, nocturnal awakenings, and MMSE performance. We chose to focus on Aβ
deposition in the precuneus for mediation analysis because of the particular vulnerability of the
precuneus to Aβ accumulation,33 its emerging role in modulating slow-wave sleep,34-36 and our
empirical finding that Aβ deposition in the precuneus had the strongest association with nocturnal
awakenings. We found via mediation analysis that Aβ and MMSE performance were not directly
associated (B = −1.55; 95% CI, −6.42 to 3.32; P = .50), consistent with the correlational data
presented in Figure 2. However, when nocturnal awakening was introduced to the analysis as part of
an indirect pathway, a statistically significant association between Aβ and poor MMSE performance
was detected (B = −5.54; 95% CI, −10.24 to −0.85; P = .02). Finally, by comparing the strength of
association between Aβ and poor MMSE performance in the direct vs indirect pathways, we found
that nocturnal awakenings mediated the association between Aβ and poor MMSE performance
(B = −3.99; 95% CI, −7.88 to −0.83; P = .01).

Figure 2. Associations of Nocturnal Awakenings With β-Amyloid (Aβ) Deposition and Mini-Mental State Examination (MMSE) Performance
A

B
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Discussion
In patients with cognitive disorders, daytime sleepiness was associated with Aβ burden in the
brainstem, whereas nocturnal awakenings were associated with Aβ burden in the precuneus.
Importantly, only nocturnal awakenings were associated with poor performance on the MMSE.
Moreover, an indirect association between Aβ and cognitive impairment was found to rely on
nocturnal awakenings as an intermediary.
The associations of different sleep behaviors with Aβ deposition in specific brain regions are
worth noting. For example, the association between daytime sleepiness and Aβ deposition in the
brainstem of individuals with cognitive impairment has not been previously reported to our
knowledge. Given the important role of the brainstem in attention and arousal,37,38 future
investigation of the downstream consequences of brainstem Aβ deposition is warranted. Moreover,
nocturnal awakenings exhibited a significant association with Aβ deposition in the precuneus, an
interesting finding to consider in light of recent evidence demonstrating the role of the precuneus in
facilitating slow-wave sleep34,36 and the implications of default-mode network dysfunction in sleep
disruption.35 Future elucidation of how precuneus abnormalities intersect with sleep and cognition is
likely vital to improving understanding of disease processes that underlie various dementia
syndromes.
Previous studies have demonstrated that individuals with normal cognition and excessive
daytime sleepiness have increased risk of cortical Aβ accumulation and cognitive decline.10,19 These

Figure 3. Mediation Analysis of Associations Between β-Amyloid (Aβ) Deposition, Nocturnal Awakenings (NAs),
and Mini-Mental State Examination (MMSE) Performance
A PET scans
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A, Representative Aβ positron emission tomography
(PET) scan images from 3 different patients who report
a mean of 1, 4.5 (ie, 4-5), and 8 NAs are shown. The
MMSE scores are also displayed. Top and bottom rows
of images show left midsagittal and right lateral views
of the brain, respectively. Scale bar indicates units of
standardized uptake ratio value (SUVR), with higher
SUVRs indicating higher levels of Aβ deposition. B, The
direct pathway between Aβ deposition in the
precuneus and MMSE performance is not significant
(B = −1.55; 95% CI, −6.42 to 3.32; P = .50). However,
an indirect pathway connecting Aβ deposition in the
precuneus to poor MMSE performance via NAs is
significant (B = −5.54; 95% CI, −10.24 to −0.85;
P = .02). Nocturnal awakening is a significant mediator
of the association between Aβ and poor MMSE
performance (B = −3.99; 95% CI, −7.88 to −0.83;
P = .01). Unstandardized regression weights (B) are
shown for every pathway in the diagram. Solid arrows
denote significant associations. The dashed arrow
denotes no significant association.
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associations were not observed in the present study, which may, in part, reflect the limitations of the
MMSE in detecting subtle cognitive changes that occur in early stages of dementia. Therefore, future
evaluation with more comprehensive neuropsychological testing is needed. Another possibility to
consider is that a mechanistic shift may occur during the transition from normal aging to disease. In
other words, factors leading to daytime sleepiness, which are likely important for the development of
dementia in individuals with normal cognition, may evolve after the onset of dementia to have more
complex associations with cognitive decline.
The finding that nocturnal awakenings are negatively associated with MMSE performance is
consistent with previous polysomnographic data showing that wakefulness after sleep onset is
associated with cognitive impairment.39 In addition, the results of this study provide novel insight by
highlighting the role that Aβ may play in nocturnal awakenings and demonstrating that the
association of Aβ with cognitive impairment relies on nocturnal awakenings as an intermediary. The
indirect association of Aβ with cognitive impairment in patients with cognitive disorders may be
important to consider given the failures of antiamyloid immunotherapy to improve cognition in
clinical trials.40 Our data suggest that a combinational approach targeting both Aβ and sleep
dysfunction may be necessary. Notably, recent studies41,42 indicate that tau may be a proximal
mediator of sleep dysfunction, suggesting that therapeutic strategies targeting both Aβ and tau may
be beneficial. Data from animal models of disease18,43 also demonstrate the contribution of
corticothalamic circuit dysfunction to wakefulness after sleep onset, a mechanism that needs to be
further explored in humans.

Limitations
Although mediation analysis is a powerful tool that can disentangle direct and indirect associations
among multiple variables of interest, an important point to keep in mind is that the analysis uses
observational data to draw pathways of association, not causation. In particular, mediation analysis
does not assess for the presence or absence of unmeasured variables, which can potentially be
confounding and limit interpretation of causality. Therefore, the results of this study should only be
interpreted as observational and associative, and a future interventional study would be needed to
establish a causative pathway between Aβ, nocturnal awakenings, and cognitive impairment. We
also acknowledge that the amount of time elapsed between MMSE testing and sleep questionnaire
administration is a potential source of variability in the study. Other limitations include not assessing a
wider range of sleep behaviors, such as napping. Sleep disorders other than sleep apnea were also
not assessed. The lack of objective sleep data in this study precluded detailed evaluation of the effect
of nocturnal awakenings on different sleep stages. Future studies should evaluate the relative
contributions of rapid eye movement and non–rapid eye movement sleep disturbances to cognitive
impairment.16,39,41 Longitudinal studies with larger sample sizes are also necessary to explore how
sleep dysfunction evolves over time.

Conclusions
In elderly individuals with cognitive disorders, Aβ accumulation is indirectly associated with cognitive
impairment via nocturnal awakenings as an intermediary. Future investigation of the mechanism
underlying this indirect association may be crucial for improved understanding of cognitive decline
in disorders associated with Aβ accumulation.
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